PURPOSE: There are limited data available in the oncology literature regarding the risk of thrombocytopenia associated with carboplatin-based second-line treatment of ovarian cancer, outside the setting of patients participating in clinical trials. METHODS: To examine this clinically-relevant issue, we conducted a retrospective review of the medical records of women with ovarian cancer treated in the Gynecologic Cancer Program of the Cleveland Clinic from 1994 through November 2003, who received >2 second-line carboplatin-based regimens. RESULTS: A total of 176 second-line carboplatin-based programs were delivered to the 152 patients (median age 61 years; range 39-87 years) identified through this review. A total of ten (7%) patients experienced >grade 2 thrombocytopenia, with only four (3%) patients developing platelet count nadirs <50.0 x 10(9)/l. No patient required discontinuation of platinum-based therapy due to the development of thrombocytopenia. CONCLUSION: Second-line carboplatin-based chemotherapy of ovarian cancer is associated with a low incidence of serious thrombocytopenia, if a strategy of selecting modest initial dose levels, and instituting rapid reductions in dose with the development of significant bone marrow suppression, is employed.
PURPOSE: There are limited data available in the oncology literature regarding the risk of thrombocytopenia associated with carboplatin-based second-line treatment of ovarian cancer, outside the setting of patients participating in clinical trials. METHODS: To examine this clinically-relevant issue, we conducted a retrospective review of the medical records of women with ovarian cancer treated in the Gynecologic Cancer Program of the Cleveland Clinic from 1994 through November 2003, who received >2 second-line carboplatin-based regimens. RESULTS: A total of 176 second-line carboplatin-based programs were delivered to the 152 patients (median age 61 years; range 39-87 years) identified through this review. A total of ten (7%) patients experienced >grade 2 thrombocytopenia, with only four (3%) patients developing platelet count nadirs <50.0 x 10(9)/l. No patient required discontinuation of platinum-based therapy due to the development of thrombocytopenia. CONCLUSION: Second-line carboplatin-based chemotherapy of ovarian cancer is associated with a low incidence of serious thrombocytopenia, if a strategy of selecting modest initial dose levels, and instituting rapid reductions in dose with the development of significant bone marrow suppression, is employed.
Authors: G Bolis; G Scarfone; G Giardina; A Villa; G Mangili; M Melpignano; M Presti; S Tateo; M Franchi; F Parazzini Journal: Gynecol Oncol Date: 2001-04 Impact factor: 5.482
Authors: F Joly; J F Héron; P Kerbrat; J Chauvergne; M Rios; F Mayer; P Chinet-Charrot; A Goupil; D Lebrun-Jezekova; D Vennin; C Lhommé; J Macé-Lesec'h; H Crouet Journal: Gynecol Oncol Date: 2000-09 Impact factor: 5.482
Authors: Allan Covens; Mark Carey; Peter Bryson; Shailendra Verma; Michael Fung Kee Fung; Mary Johnston Journal: Gynecol Oncol Date: 2002-04 Impact factor: 5.482
Authors: W P McGuire; W J Hoskins; M F Brady; H D Homesley; W T Creasman; M L Berman; H Ball; J S Berek; J Woodward Journal: J Clin Oncol Date: 1995-07 Impact factor: 44.544
Authors: M Gore; P Mainwaring; R A'Hern; V MacFarlane; M Slevin; P Harper; R Osborne; J Mansi; P Blake; E Wiltshaw; J Shepherd Journal: J Clin Oncol Date: 1998-07 Impact factor: 44.544
Authors: Roisin O'Cearbhaill; Qin Zhou; Alexia Iasonos; Martee L Hensley; William P Tew; Carol Aghajanian; David R Spriggs; Stuart M Lichtman; Paul J Sabbatini Journal: Gynecol Oncol Date: 2009-11-27 Impact factor: 5.482